ADAP: רווח נקי למניה (EPS TTM) Adaptimmune Therapeutics plc

The rolling earnings per share trend demonstrates the impact of the innovative Tecelra launch on financial performance, with the latest reading standing at -0.65. Adaptimmune's authority in treating solid tumors strengthens market confidence, although high drug launch costs and competition in oncology create risks. Investors see real cost pressure through the EPS dynamics.

This indicator is calculated as the ratio of total net income to the total number of shares outstanding. It determines the portion of profit attributable to a single security over the last twelve months. Outsourcing clinical trials to external contractors helps Adaptimmune (ADAP) optimize R&D expenses, directly impacting final profitability. By analyzing the company's rolling annual earnings per share, an investor assesses the efficiency of capital management. The trend of this line signals the degree of stability in the business's margins.